Document 0974
 DOCN  M9570974
 TI    Lowered minimal erythema dose (med) at 297 nm UVB but not at 360 nm UVA
       under recombinant interferon alpha (Meeting abstract).
 DT    9506
 AU    Hohenbleicher H; Gollnick HP; Department of Dermatology, University
       Medical Center Steglitz,; The Free University of Berlin, Berlin, Germany
 SO    Melanoma Res; 3:21 1993. Unique Identifier : AIDSLINE ICDB/95607257
 AB    Recombinant alpha-interferon, a biological immune response modifier, is
       an established therapeutic agent for benign and malignant diseases. In
       dermatology it is intensively used for cutaneous T-cell lymphomas
       (CTCL), malignant melanoma (MM) and Kaposi's sarcoma (KS) in
       HIV-infection either alone or in combination with
       cytostatic/noncytostatic drugs. Besides, well known adverse drug
       reactions (ADR) of IFN alpha, clinical observations in patients
       suffering from cutaneous T-cell-lymphomas under combined regimen with
       PUVA (psoralens plus UVA) and recombinant interferon alpha 2
       (rIFNalpha-2) showed increased photosensitivity. The aim of the present
       study was to evaluate phototoxic ADR of rIFNalpha by measuring the
       dynamic of the MED at 297 mn and 360 mn before and under administration
       of alphaIFN. We studied 7 patients with malignant melanoma, 7 with CTCL
       and 5 with KS in HIV-infection. Four days before and 6 hours after sc
       application of 9 million IE rIFNalpha-2a patients were exposed to 297 nm
       UVB (6 doses: range 12.5 to 98.7 ml/cm2) and to 360 nm UVA (6 doses:
       range 1 to 20 J/cm). After 24, 48 and 72 hours the development of
       erythema was assessed visually and by a Minolta Chromameter (CIE:
       Commission Internationale d'Eclairage, 1976). Results are presented in a
       table. The MED and delta(a) for UVA 360 nm was not significantly changed
       in all patients, however, a trend was noted in CTCL patients. From our
       results it can be concluded that patients under rIFNalpha-2 therapy
       should be informed about higher sensitivity to natural and artificial
       UV-light. Therefore, the use of sunblocks during outdoor UV-exposure
       should be recommended. Whether skin conditions like in CTCL and HIV-KS
       patients predispose for enhanced photosensitivity compared to
       MM-patients has to be further studied. In combined
       PUVA-rIFNalpha-2-regimen the irradiation doses have to be adjusted. At
       the moment it is rather speculative why UVA plus IFNalpha did not
       increase significantly the UV-sensitivity; however, it could be
       explained in three ways: (1) a too small test-group, (2) test-dose too
       low, (3) UV-lamps used in clinical trials emitted small amounts of the
       UVA2-UVB border-wavelengths, and (4) only IFNalpha + 8-MOP/UVA is
       phototoxic.
 DE    Erythema/*ETIOLOGY  Human  Interferon-alpha/*THERAPEUTIC USE  Lymphoma,
       T-Cell/*RADIOTHERAPY  Melanoma/*RADIOTHERAPY  Recombinant
       Proteins/THERAPEUTIC USE  Sarcoma, Kaposi's/*RADIOTHERAPY  Skin
       Neoplasms/*RADIOTHERAPY  *Ultraviolet Rays  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).